Analytical Data
-
Gene name
MD1
- Application
-
Alternative Names
MD1；MD1；Lymphocyte antigen 86
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95711
-
Expression Region
21-162aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSGGGGKAW PTHVVCSDSG LEVLYQSCDP LQDFGFSVEK CSKQLKSNIN IRFGIILRED IKELFLDLAL MSQGSSVLNF SYPICEAALP KFSFCGRRKG EQIYYAGPVN NPEFTIPQGE YQVLLELYTE KRSTVACANA TIMCS
-
Molecular Weight
18 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MD1 recombinant protein has emerged as a significant focus of research in the field of immunology and vaccine development. MD1, a member of the immune receptor family, plays a crucial role in modulating immune responses, particularly in the context of autoimmune diseases and infections. Its distinct structure and function contribute to the regulation of T-cell activation and the maintenance of immune homeostasis. Recent studies have demonstrated that the manipulation of MD1 can enhance the efficacy of therapeutic interventions, potentially leading to new treatment strategies for various diseases. The recombinant production of MD1 allows for in-depth analysis of its biological properties and interaction with other immune components. Additionally, this research paves the way for the development of MD1-based vaccines, capable of eliciting targeted immune responses and improving resistance to specific pathogens. As the understanding of MD1's mechanisms evolves, it promises to provide valuable insights into the design of innovative immunotherapies, thereby holding great potential for clinical applications in enhancing immune function and combating diseases.
